Celgene International Sárl (CELG) Release: REVLIMID® Evaluated in Combination with Rituximab as a Potential Treatment for Patients with Treatment-Naive Chronic Lymphocytic Leukemia
12/13/2011 1:48:06 PM
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced results from an investigational study evaluating REVLIMID (lenalidomide) in combination with rituximab in patients with treatment-naive chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.
comments powered by